Drugs / sodium N-(8-[2-hydroxybenzoyl] amino) caprylate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03010475 | Jan → Jun 2017 | diabetes mellitus | Novo Nordisk A/S | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sodium N-(8-[2-hydroxybenzoyl] amino) caprylate | “The first oral glucagon-like peptide-1 receptor agonist (GLP-1RA) comprises semaglutide co-formulated with the absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino)...” PMID 33782832 ↗ Sep 2021 |
| Known as | SNAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03010475 ↗ |
| Route | Oral | “Oral administration. A total of five single doses.” NCT03010475 ↗ |